HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Corvera, J. S. Articles by Vinten-Johansen, J. Search for Related Content PubMed PubMed Citation Articles by Corvera, J. S. Articles by Vinten-Johansen, J. Related Collections Myocardial protection

Ann Thorac Surg 2003;76:1614-1622
© 2003 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Optimal dose and mode of delivery of Na⁺/H⁺ exchange-1 inhibitor are critical for reducing postsurgical ischemia-reperfusion injury

^a Cardiothoracic Research Laboratory and Carlyle Fraser Heart Center, Emory University School of Medicine, Atlanta, Georgia, USA
^b Merck KGaA, Darmstadt, Germany

Accepted for publication May 29, 2003.

^* Address reprint requests to Dr Vinten-Johansen, Cardiothoracic Research Laboratory, Carlyle Fraser Heart Center, 550 Peachtree St, NE, Atlanta, GA 30308, USA.
e-mail: jvinten{at}emory.edu

BACKGROUND: In clinical trials, perioperative intravenous Na⁺/H⁺ exchange isoform-1 (NHE1) inhibitors were only moderately effective in high-risk patients undergoing surgical reperfusion (GUARDIAN trial). However, effective myocardial concentrations of NHE1 inhibitor may not have been achieved by parenteral administration alone. We tested the hypothesis that increasing doses of NHE1 inhibitor EMD 87580 ((2-methyl-4,5-di-(methylsulfonyl)-benzoyl)-guanidine) delivered in blood cardioplegia (BCP) and by parenteral route at reperfusion reduce myocardial injury after surgical reperfusion of evolving infarction.

METHODS: Twenty-six anesthetized dogs underwent 75 minutes of left anterior descending coronary artery occlusion, followed by cardiopulmonary bypass and 60 minutes of arrest with multidose 10°C BCP. In the control group (n = 8), BCP was not supplemented. In the three EMD-BCP groups, BCP was supplemented with 10 µmol/L EMD 87580 (EMD-10, n = 5), 20 µmol/L EMD 87580 (EMD-20, n = 5), or 20 µmol/L EMD 87580 combined with an immediate reperfusion bolus (5 mg/kg intravenously) (EMD-20R, n = 8). The left anterior descending coronary artery occlusion was released just before the second infusion of BCP. Reperfusion continued for 120 minutes after discontinuation of cardiopulmonary bypass.

RESULTS: Postischemic systolic and diastolic function in the area at risk was dyskinetic in all groups. Infarct size (percentage of area at risk) was not significantly reduced in the EMD-10 (26.2% ± 3.6%) and EMD-20 (22.5% ± 2.4%) groups versus control (30.7% ± 2.4%); however, infarct size was significantly reduced in the EMD-20R group (16.1% ± 2.8%, p = 0.003). Edema in the area at risk in the EMD-10 (81.1% ± 0.5% water content), EMD-20 (81.7% ± 0.3%), and EMD-20R (81.9% ± 0.3%) groups was less than in controls (83.2% ± 0.2%), (p < 0.056). Neutrophil accumulation (myeloperoxidase activity) in postischemic area-at-risk myocardium was less in the EMD-20R group versus the control group (5.3 ± 0.7 versus 8.7 ± 1.4 absorbance units · min^-1 · g^-1; p = 0.05), which suggests an attenuated postischemic inflammatory response.

CONCLUSIONS: Optimal delivery of NHE1 inhibitor to the heart through combined cardioplegia and parenteral routes significantly attenuates myocardial injury after surgical reperfusion of regional ischemia. Timing, dose, and mode of delivery of NHE1 inhibitors are important to their efficacy.